FBIO
Fortress Biotech, Inc.
There isn't enough reported data to score FBIO yet.
FBIO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Unavailable | |
| Unavailable |
FBIO's revenue is currently healthy, and its profitability is stable. There isn't enough data to rate its cash flow and balance sheet.
FBIO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 0.7x | $2.01 | +0.8% |
| Current | 0.7x | $1.99 | — |
| Fair | 0.9x | $2.32 | +17% |
| Expensive | 1x | $2.77 | +39% |
Historical ranges are pointers, not guarantees.
FBIO's PE is 0.7x, but its earnings don't support one, so it isn't a reliable read right now.
FBIO Forward outlook
There aren't enough analyst estimates for FBIO to show an outlook.
FBIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $2.70 | +$3.66 |
| Q1 2026 | $3.23 | +$5.37 |
| Q4 2025 | -$0.07 | +$2.62 |
| Q3 2023 | -$12.19 | +$3.56 |
| Q2 2023 | -$15.00 | +$0.90 |
| Q1 2023 | -$15.00 | -$2.10 |
| Q4 2022 | -$14.55 | -$2.70 |
| Q3 2022 | -$15.75 | -$8.55 |
FBIO has returned to profit: it earned $2.70 per share over the past year, after losing money the year before.
FBIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $18.7M | +14% |
| Q1 2026 | $16M | +22% |
| Q4 2025 | $16.1M | +6.3% |
| Q3 2025 | $17.6M | +21% |
| Q2 2025 | $16.4M | +10% |
| Q1 2025 | $13.1M | +0.8% |
| Q4 2024 | $15.1M | -24% |
| Q3 2024 | $14.6M | -58% |
FBIO's revenue is recovering but still below its 2023 peak: $19M last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -53% | +169 points |
| Q1 2026 | -48% | +122 points |
| Q4 2025 | -30% | +128 points |
| Q3 2025 | -39% | +112 points |
| Q2 2025 | -222% | -36 points |
| Q1 2025 | -170% | +111 points |
| Q4 2024 | -158% | -59 points |
| Q3 2024 | -151% | -111 points |
FBIO's operating margin was −53% last quarter, up 169 points from the same quarter a year ago.
FBIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | $203.9M | +$223.4M |
| Q4 2025 | -$12.5M | +$363K |
| Q3 2025 | -$6.1M | +$13.9M |
| Q1 2025 | -$19.6M | +$5.8M |
| Q4 2024 | -$12.9M | +$22.1M |
| Q3 2024 | -$20.1M | -$3.3M |
| Q1 2024 | -$25.4M | +$17.8M |
| Q4 2023 | -$35M | +$13M |
FBIO's free cash flow has turned positive after five years mostly in the red: $166M over the past year.
FBIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -17% | -6.6M shares |
| 1 year | +6.6% | +2M shares |
| 3 years | +437% | +25.9M shares |
| 5 years | +527% | +26.7M shares |
FBIO has 32M diluted shares, up 6.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
FBIO Net Leverage
FBIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.7 | Neutral |
| Stochastic | 8.6 | Oversold |
FBIO's weekly RSI is 38 (neutral) and its Stochastic is 9 (oversold).
FBIO PE vs Healthcare Sector
| Metric | FBIO | Sector median | Relative |
|---|---|---|---|
| PE | 0.7x | 26x | 97% below |
| PE % | 15 | 29 | 14 pts below |
FBIO is trading at 0.7x earnings, a 97% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
FBIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.00 | 0.5% below |
| 20 week MA | $2.56 | 22% below |
| 50 week MA | $2.84 | 30% below |
| 100 week MA | $2.49 | 20% below |
| 200 week MA | $3.62 | 45% below |
FBIO is in a downtrend: it's below all five of its weekly moving averages, and 45% below its 200-week average.
FBIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $37.1 | $51.5 | +39% |
| 2021 | $51.5 | $39.3 | -24% |
| 2022 | $39.3 | $8.25 | -79% |
| 2023 | $8.25 | $3.01 | -64% |
| 2024 | $3.01 | $2.36 | -22% |
| 2025 | $2.36 | $3.74 | +58% |
| 2026 YTD | $3.74 | $1.99 | -47% |
FBIO has finished lower in four of the last six years. It's down 47% so far in 2026.